323 results about "Mental dysfunction" patented technology

The present invention relates to diagnostic methods for assessing predisposition of a subject to a mental disorder phenotype having an association with an at-risk allele of a brain-functional gene having a plurality of alleles, the association being conditioned by a pathogenic environmental risk factor status condition. Additionally, the invention relates to methods for discovering a conditional association between a mental disorder phenotype and an at-risk allele of a brain-functional gene having a plurality of alleles, the association being conditioned by a pathogenic environmental risk factor status condition.

Systems and methods for treating neuro-psychiatric disorders, such as depression or schizophrenia, and / or other illnesses are disclosed. A patient is diagnosed with a particular neuro-psychiatric disorder or other illness. An electric nerve stimulation (ENS) technique, such as vagus nerve stimulation (VNS), is administered to the patient in conjunction with a magnetic nerve stimulation (MNS) technique. The magnetic nerve stimulation (MNS) technique includes applying a magnetic field to a pre-selected synaptic region of a brain of the patient based on the diagnosis. A physiological response of the brain, such as electroencephalogram (EEG) activity, is monitored. One or more parameters of the magnetic field may be selectively adapted in response to the monitored physiological response. The administration of the ENS technique and the MNS technique may be performed simultaneously, in serial order, or in alternating order depending on the diagnosis.

Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.

It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and / or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative disorder). The present invention provides: compounds having PDE10 inhibitory effect, in particular, compounds having a 4-heteroarylpyrazole-5-carboxylic acid amide structure represented by the following formula (I), or their pharmaceutically acceptable salts, or their solvates; pharmaceutical compositions comprising, as active ingredients, the compounds, or their pharmaceutically acceptable salts, or their solvates; and medical use of the compounds, or their pharmaceutically acceptable salts, or their solvates.

The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

At least one embodiment of the disclosure is directed to a method for processing brainwave signals for treating a patient having neurological disorder or mental disorder or a combination of neurological and mental disorder. The method comprises: measuring a brainwave signal from the patient, the measured brainwave signal containing noise; denoising the brainwave signal to obtain a clean brainwave signal; matching the clean brainwave signal to a database of brainwave signals for neurological or mental conditions or a combination of neurological and mental conditions to identify the patient's neurological or mental status or a combination of neurological and mental conditions; and applying a therapeutic treatment to the patient based on the identified neurological or mental status or a combination of neurological and mental conditions.

The invention discloses a school pre-warning intervention method for teenager suicide mental crisis. Through screening evaluation and graded intervention of mental crisis, pre-warning intervention is carried out on the teenager suicide mental crisis; the screening evaluation is carried out by respectively screening teenagers at higher risk of suicide and teenagers with mental disorders through questionnaire survey and psychiatrist interviews so as to determine an graded intervention object and performing common intervention, pertinent intervention or therapeutic intervention on the graded intervention object. Through the adoption of the school pre-warning intervention system and intervention method for the teenager suicide mental crisis, disclosed by the invention, suicide rate of school teenagers as well as suicide risk factors, such as depression, impulsion and the like, can be effectively reduced; and the school pre-warning intervention system and intervention method for the teenager suicide mental crisis, disclosed by the invention, can be accepted by most teenagers.

The present invention relates to novel compounds of the formula (I), wherein Het, A, Q, X1, X2, X3, R1 and R2 are defined in the specification, which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

One embodiment of an aspect of the present invention is a method for lessening the symptoms of depression, anxiety, and post-traumatic stress disorder comprising the step of administering a therapeutically effective quantity of a cholinergic M1 receptor antagonist and a therapeutically effective quantity of one or more cholinomimetic agents to lessen the symptoms of depression, anxiety, and post-traumatic stress disorder. Typically, the cholinergic M1 receptor antagonist is selected from the group consisting of telenzepine, amytriptyline, biperiden, trihexyphenidyl, darifenacin, dicyclomine, and tiotropium. Another aspect of the present invention is directed to methods and compositions employing other therapeutic agents and combinations of therapeutic agents for emulating the theoretical pharmacological effects of the non-selective mAChR antagonist scopolamine. The invention also encompasses pharmaceutical compositions incorporating one or more therapeutic agents and a pharmaceutically acceptable carrier.

Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.

The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I)wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

The present invention relates to the use of compounds and compositions of compounds having D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic activity for the treatment of the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability-hypersensitivity-hyperaesthesia-dissociative phenomena-etc). The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) compounds having D4 antagonistic, partial agonistic or inverse agonistic activity and (ii) compounds having 5-HT2A antagonistic, partial agonistic or inverse agonistic, and (iii) any known medicinal compound and compositions of said compounds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biological compound or in two different chemical and / or biological compounds.

The present invention relates to a novel purpose of hederagenin and a derivative of the hederagenin. An anti-depression test of the hederagenin and the derivative of the hederagenin shows obvious anti-depression activity, wherein, the salt derivative of the hederagenin has stronger anti-depression activity than the hederagenin; the hederagenin has stronger anti-depression activity than hederangenoside; the activities of the hederagenin and a hypericum extract are equivalent; sodium hederagenin has higher activity than the hypericum extract. The present invention has obvious pharmacological effect and stable quality; the raw material of the present invention has abundant source and cheap price and is safe with low toxin; the present invention has simple preparation technology and high yield, which provides novel medicine source for preventing, diagnosing, examining, protecting, remedying and researching on the depression and diseases directly related to the depression, is fit for the industrialization production, is easy for popularizing and applying and has very important value for developing and using Chinese officinal plant resource. Affective mental disorder is listed at top in Chinese disease general burden, and the research and manufacture of the drug for preventing and remedying the depression has obvious social benefit and economic benefit.